Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7
👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved
✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22)
✅increased time to subsequent hormonal therapy (HR 0.36)
All clinically meaningful benefits, while OS remains immature.
#ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1
8 views · 0 likes · 0 reposts · 1 reply
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org- Sabine D. Brookman-May@brookmans76
While DASL-HiCaP reinforces ARPI intensification, important questions remain @Silke_Gillessen Why positive #STAMPEDE/#DASL-HiCaP, yet not #ENZARAD? Which high-risk patients benefit most? Primary vs salvage RT? And how does #PROTEUS reshape intensification around surgery? #Enzalutamide #Apalutamide #Darolutamide ❓Different risk definitions and primary vs salvage settings complicate comparisons. ❓Who truly needs ARPI intensification, and when? What is the additive role of #RadiationTherapy and #RadicalProstatectomy ❓With PROTEUS extending the discussion to prostatectomy, better patient selection and identifying the best prognostic and predictive biomarkers reflecting specific early/local/locally advanced indications remains key #ESMO26 #ProstateCancer #UrologicOncology @oncodaily @OncoDailyGU @urotoday
Source: Sabine D. Brookman-May · x.com